azole resistance – mycolab.ai

Refractory fungal infection: Three case reports highlighting good practice

mycolabadmin

This case series examines three patients with serious fungal infections that did not respond well to standard antifungal treatments. The cases demonstrate how fungi can develop resistance to common antifungal drugs like azoles, making infections harder to treat. The authors emphasize that accurate identification of the fungus, testing its sensitivity to drugs, monitoring drug levels in the blood, and careful use of antifungal medications are essential for successfully treating these difficult infections.

Clinical and Genomic Insights into Antifungal Resistance in Aspergillus Isolates from Thailand

mycolabadmin

Researchers in Thailand identified a dangerous fungal infection caused by Aspergillus fumigatus that is resistant to azole antifungal drugs. This is the first time this specific drug-resistant strain has been found in a patient sample in Thailand, though it had been previously detected in environmental samples. The study used genetic testing to understand how the fungus developed resistance and found that it has altered genes that help it survive the antifungal medications commonly used to treat infections.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against dangerous fungal infections caused by Aspergillus species. The drug works by removing important minerals like zinc that these fungi need to survive. Testing showed nitroxoline was very effective against these fungi, even against strains that had developed resistance to modern antifungal drugs. This suggests nitroxoline could potentially be repurposed as a new treatment option for serious fungal infections.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection on his replacement heart valve after recent surgery. The fungal infection was caused by a type of yeast called Candida glabrata that was resistant to the initial antifungal medication. After testing revealed resistance and biofilm formation, doctors switched to caspofungin, a stronger antifungal drug, and the patient recovered successfully.

Leveraging synthetic genetic array screening to identify therapeutic targets and inhibitors for combatting azole resistance in Candida glabrata

mycolabadmin

Candida glabrata is a dangerous fungus causing serious infections that is becoming resistant to antifungal drugs. Researchers used a genetic screening technique to find genes that interact with drug resistance mutations and identified methotrexate (a drug already used for arthritis) as a potential partner for fluconazole treatment. When combined, these drugs work better together against resistant strains of the fungus, offering hope for treating these stubborn infections.

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, which are particularly dangerous for people with weakened immune systems. The researchers found that while most hospitals can test fungal samples, not all have access to all necessary diagnostic tools, especially tests for detecting resistant fungi and identifying fungal co-infections. Many hospitals outsource their testing to other facilities, which can delay diagnosis and treatment, and some hospitals lack access to all recommended antifungal medications.

Aspergillus fumigatus ctf1 – a novel zinc finger transcription factor involved in azole resistance

mycolabadmin

Researchers discovered that a gene called ctf1 in a harmful fungus called Aspergillus fumigatus helps control how resistant the fungus is to antifungal medications like voriconazole. When this gene is removed, the fungus becomes more resistant to these drugs because it pumps them out more efficiently. Understanding this mechanism could help doctors develop better treatments for serious fungal infections in vulnerable patients.

Recalcitrant dermatophytosis due to Trichophyton indotineae: A case series from Sarawak, Malaysia

mycolabadmin

Three patients in Malaysia had persistent skin fungal infections caused by Trichophyton indotineae that did not respond to standard antifungal treatments. Genetic testing revealed these fungal strains carried a specific mutation making them resistant to terbinafine, the typical first-line treatment. While azole-based antifungals showed variable effectiveness depending on the specific drug and dose used, one patient achieved complete cure with voriconazole therapy. The study highlights the growing problem of drug-resistant fungal infections and the importance of targeted treatment based on laboratory testing.

RttA, a Zn2-Cys6 transcription factor in Aspergillus fumigatus, contributes to azole resistance

mycolabadmin

Researchers discovered that a protein called RttA helps a common fungus called Aspergillus fumigatus resist azole medicines, which are used to treat serious fungal infections. By studying how this protein works and which genes it controls, scientists found that RttA could be a new target for developing better antifungal treatments. The findings are important because azole-resistant fungal infections are becoming more common worldwide and harder to treat.

Aspergillus fumigatus ctf1 – a novel zinc finger transcription factor involved in azole resistance

mycolabadmin

A. fumigatus is a dangerous fungal infection that kills many immunocompromised patients and increasingly resists common antifungal drugs. Researchers identified a key protein called ctf1 that helps the fungus resist the drug voriconazole by pumping it out of fungal cells and altering the fungal cell membrane. Understanding how ctf1 works could lead to new treatments for these difficult-to-treat infections.

Research Topic: azole resistance